15-min delayed · Sep 9, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 20 firms covering Abbott Laboratories, 20 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets are tightly clustered, $112.00 to $146.00, so the covering firms are broadly aligned. The average target of $125.26 sits 19% above the current $105.26. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 16 to 20 over recent months. On the fundamentals, the Street sees revenue growth near 13% this year and 9% next, consensus EPS building from about $1.64 next quarter toward $6.06 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS20 ratings
Strong Buy
Strong Buy00%
Buy20100%
Hold00%
Sell00%
Strong Sell00%
Based on 20 analysts giving stock ratings to Abbott Laboratories.
As of Sep, 20 of 20 firms rate ABT a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
ABT EPS & revenue forecast
EPS · NEXT QUARTER
$1.64
Range $1.59 – $1.67 · 22 analysts · +9% YoY
Next period, 22 analysts expect Abbott Laboratories to earn $1.64 a share (range $1.59 – $1.67), versus $1.50 a year earlier. Full-year consensus is $5.52, growing to $6.06 the year after.
REVENUE · NEXT QUARTER
$13.5B
Range $13.3B – $13.7B · 22 analysts · +16% YoY
Revenue is expected to reach $13.5B (range $13.3B – $13.7B), +16.0% year-over-year. Full-year consensus is $50.3B, rising to $54.6B next year.
Top analysts covering Abbott Laboratories
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ABT.
#1
Anthony Petrone
Mizuho · Rank #86
Hold
$115.00+9.3% to target
Overall win rate
46%
+ Follow
#2
JB
Jayson Bedford
Raymond James · Rank #196
Buy
No targeton ABT
Overall win rate
42%
+ Follow
#3
Bruce Jackson
Benchmark · Rank #374
Buy
$120.00+14.0% to target
Overall win rate
36%
+ Follow
#4
MT
Marie Thibault
BTIG
Buy
$134.00+27.3% to target
Coverage
—
+ Follow
#5
Vijay Kumar
Evercore ISI Group
Buy
$120.00+14.0% to target
Coverage
—
+ Follow
ABT stock forecast FAQ
What is ABT's average 12-month price target?+
The 19 analysts with a live target average $125.26 for Abbott Laboratories over the next 12 months, ranging from a $146.00 high to a $112.00 low.
Is ABT stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 20 analyst ratings, 20 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for ABT?+
The Street-high target is $146.00 (Raymond James), and the Street-low is $112.00 (Wells Fargo). The average of all 19 active targets is $125.26.
How many Wall Street analysts cover ABT?+
20 analysts have an active rating on Abbott Laboratories, and 19 firms carry a live 12-month price target.
Who is the most accurate analyst covering ABT?+
Among analysts who currently cover ABT, Anthony Petrone of Mizuho has the strongest overall Quantellect track record (Rank #86). Their current call is Hold with a $115.00 target.
What is Abbott Laboratories's projected EPS for next quarter?+
The consensus estimate is $1.64 per share (range $1.59 – $1.67) across 22 analysts. Full-year EPS is projected at $5.52, rising to $6.06 the following year.
How much revenue is Abbott Laboratories expected to report next quarter?+
Consensus revenue is $13.5B (range $13.3B – $13.7B). Full-year revenue is projected at $50.3B, growing to $54.6B next year.
Have analysts been upgrading or downgrading ABT lately?+
As of Sep, 20 of 20 firms rate ABT a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ABT calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
UBS
